Key takeaways from the G-FINDER survey
- Overall funding for global health R&D declined by a little under 6% in 2024, to $8.7bn, but three-quarters of the decline was due to reduced COVID funding.
- Funding specifically for neglected disease R&D fell slightly (by $98m, -3%) in 2024.
- Funding specifically for women’s health rose a little, by $29m (4%), thanks to rising spending on STIs, which more than offset falling HPV R&D.
- Funding for non-COVID EIDs experienced a moderate decline in 2024 (of around $140m, or -7%) after growing by more than a third ($647m) in 2023.
- The ongoing decline in COVID R&D slowed slightly, with spending falling by $383m (-17%) after dropping by nearly $6bn over the previous two years.
- 'Crossover’ funding for more than one global health area rose by another $100m (22%)
